We hypothesized that NfL would be a better biomarker for spinal cord degeneration than GFAP, since axonal rather than glial degeneration is the pathological hallmark of myelopathy in ALD.7 The gene discussed is GFAP; the disease is X-linked adrenoleukodystrophy.